Evolus, Inc. Common Stock (EOLS) Financials
EOLS Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2024-03-31 | 226.2 million | 207.7 million |
2023-12-31 | 189.0 million | 209.7 million |
2023-09-30 | 168.0 million | 187.3 million |
2023-06-30 | 169.0 million | 175.9 million |
EOLS Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2024-03-31 | -11.4 million | 5.1 million |
2023-12-31 | 452000 | 4.4 million |
2023-09-30 | -35.4 million | 4.6 million |
2023-06-30 | -13.5 million | 4.2 million |
EOLS Net Income
No data available :(
EOLS Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2024-03-31 | 97.0 million | - | 6.0 million |
2023-12-31 | 62.8 million | - | 6.2 million |
2023-09-30 | 38.7 million | - | 6.3 million |
2023-06-30 | 41.7 million | - | 2.0 million |
EOLS Shares Outstanding
EOLS Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2024-03-31 | 797000 | 2.1 million | 45.1 million | - |
2023-12-31 | 361000 | 2.4 million | 35.6 million | 7.5 million |
2023-09-30 | 539000 | 1.6 million | 43.3 million | - |
2023-06-30 | 216000 | 1.2 million | 42.9 million | - |
EOLS Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2024-03-31 | 59.3 million | 19.5 million |
2023-12-31 | 61.0 million | 20.6 million |
2023-09-30 | 49.3 million | 15.4 million |
2023-06-30 | 49.3 million | 14.7 million |
EOLS
Price: $13.59
52 week price:
Earnings Per Share: -1.08 USD
P/E Ratio: -12.23
Exchange: NGM
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Volume: 16622
Market Capitalization: 798.3 million